Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
When choosing a weight loss medication, patients often compare phentermine—a decades-old stimulant—with newer GLP-1 receptor agonists like semaglutide (Ozempic). Clinical trials show GLP-1 medications produce significantly greater weight reduction and metabolic benefits, but the right choice depends on individual health status, genetic factors, and treatment goals.
How Phentermine and Semaglutide Work Differently
Phentermine acts as a sympathomimetic amine, stimulating the central nervous system to increase heart rate, blood pressure, and appetite suppression. It was developed in the 1950s and works primarily through norepinephrine release, creating a short-term energy boost and reduced hunger signals. The medication typically produces modest weight loss of 5 to 10 pounds over 12 weeks in clinical settings.
Semaglutide, a GLP-1 receptor agonist, mimics glucagon-like peptide-1—a hormone that regulates blood sugar, appetite, and gastric emptying. By activating GLP-1 receptors throughout the brain and gut, semaglutide slows stomach emptying, increases feelings of fullness, and improves blood sugar control. Landmark trials demonstrate average weight loss of 15 to 22 percent of body weight over 68 weeks, substantially exceeding phentermine outcomes.
Clinical Evidence: Weight Loss Results Comparison
Phentermine approval trials from decades ago showed average weight loss of 5 to 10 pounds beyond diet and exercise alone, with effects often plateauing after 12 weeks. Long-term data on phentermine remains limited because the FDA historically approved it for short-term use only (12 weeks or less), though some physicians prescribe it off-label for extended periods.
Semaglutide clinical trials (STEP program) enrolled over 4,500 participants and measured weight loss over 68 weeks. Participants receiving semaglutide 2.4 mg weekly lost an average of 22 percent of their starting body weight compared to 2 percent in the placebo group. Additionally, semaglutide improved cardiovascular outcomes, reduced blood pressure, and enhanced insulin sensitivity—benefits not demonstrated with phentermine.
Side Effects and Safety Profile Differences
Phentermine side effects stem from its stimulant action and include increased heart rate, elevated blood pressure, insomnia, anxiety, and potential for dependence with prolonged use. Some patients experience jitteriness, headaches, and dry mouth. The medication carries contraindications for patients with uncontrolled hypertension, coronary artery disease, or histories of substance abuse.
Semaglutide's most common side effects are gastrointestinal—nausea, vomiting, diarrhea, and constipation—which typically diminish as the body adjusts over weeks. Unlike phentermine, semaglutide does not increase heart rate or blood pressure and carries no abuse potential. Serious but rare risks include pancreatitis and retinal complications in patients with preexisting diabetic retinopathy, making medical supervision essential.
Who Benefits More From Each Medication
Phentermine may be appropriate for patients seeking short-term appetite suppression, those unable to tolerate GLP-1 side effects, or individuals with specific contraindications to GLP-1 agonists. However, its modest efficacy and limited long-term data make it a second-line option for most weight loss candidates.
Semaglutide suits patients with significant weight to lose, those with type 2 diabetes, metabolic syndrome, or cardiovascular risk factors. Genetic factors also influence response: the Precision Peptide Genetic Test examines GLP1R rs6923761 and other variants that predict individual sensitivity to GLP-1 therapy, allowing PlexusDx to personalize dosing and medication selection. Patients seeking sustained, evidence-based weight management with cardiovascular protection typically achieve superior outcomes with semaglutide or compounded tirzepatide.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic approved for weight loss?
Ozempic (semaglutide) is FDA-approved for type 2 diabetes. Wegovy, a higher-dose semaglutide formulation, is approved specifically for chronic weight management. PlexusDx offers compounded semaglutide injection starting at $149/month from licensed 503A pharmacies, serving patients nationwide without requiring insurance.
Can phentermine and semaglutide be used together?
Combining phentermine with GLP-1 agonists is not standard practice and carries theoretical risks due to overlapping mechanisms. Most clinicians recommend choosing one approach. PlexusDx providers can evaluate individual cases and recommend the most appropriate medication based on medical history and genetic testing results.
How long can I take phentermine versus semaglutide?
Phentermine is traditionally approved for 12 weeks or less, though some prescribers use it longer off-label. Semaglutide is designed for chronic, long-term use; patients continue therapy as long as they tolerate it and benefit clinically. PlexusDx patients maintain access to compounded semaglutide at flat monthly pricing regardless of dose escalation.
Which medication causes fewer side effects?
Phentermine's stimulant effects (elevated heart rate, anxiety, insomnia) trouble many patients, while semaglutide's gastrointestinal side effects usually fade within weeks. Semaglutide carries no stimulant burden and is safer for patients with hypertension or cardiac concerns. Individual tolerance varies, which is why genetic and medical assessment informs the best choice.
Does the Precision Peptide Genetic Test predict which medication works better?
PlexusDx's Precision Peptide Genetic Test (add-on after first month, $99) analyzes 14 pathways including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 variants that influence GLP-1 responsiveness. Results guide medication selection and dosing optimization, helping patients achieve faster, more significant weight loss with personalized therapy.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Ozempic and Prozac: What to Know About This Combination
Smooth Travels: Expert Tips for Flying with Ozempic and Your Weight Loss Journey